Over 1 billion inhalers Suzhou Hongsen Pharmaceuticals has been evaluated in the immediate

Pharmaceutical Network July 9th, July 1, Suzhou Hongsen Pharmaceuticals to copy the 4 categories of inhalation of salistate sulfate amineol solution listing application into the administrative approval stageAccording to Minnet.com, sales of salbutamol inhalers at the end of public medical institutions in China in 2019 were RMB1,123 million, up 20% YoY, the first evaluated variety of flowers in Hebei Renhe Yikang PharmaceuticalSSalbutamol belongs to selective beta 2 receptor agonists, which can effectively inhibit the release of allergic substances such as histamine, prevent bronchospasm, and are clinically used to treat bronchosis, wheezing bronchosis, bronchospasm, emphysema, etcAt present, domestic market salbutamol has tablets, capsules, inhalants, injections, among which inhalants are the most widely usedFigure: Sales of salbutamol inhalers in terminals in public medical institutions in China from 2015 to 2019 (units: 10,000 yuan)net data show that in recent years, salbutamol inhalers (including aerosols, inhaling solution) have increased year by year in
china's publichospitals, county-level public hospitals, urban community centers and township hospitals (China Public Medical Institutions) and the growth rate has been maintained at more than 20% in 2019Table: Inhalation of sulphate salbutamol solution new classification reporting in the review of the situation
minnet network data show that there are currently 7enterprises in Chinawith the new registration classification submitted applications for the application for inhalation of sulfate sulfateamine solution, Hebei Renhe Yikang Pharmaceutical products in February 2020 was approved for production and as reviewed as the first in China;Source: Minnet databaseNote: statistics as of July 8, if there are omissions, welcome to point!